Follicular Lymphoma
Stay at the forefront of follicular lymphoma care with insights from the Lancet, featuring groundbreaking research and authoritative reviews that inform the latest advances in diagnosis, treatment, and patient care.
Research in Context
Research in Context is a structured summary that editors at The Lancet’s journals ask all authors to provide when submitting an original research article. Read more
Featured Article
Phase 3 EPCORE FL-1: epcoritamab plus R² in relapsed or refractory follicular lymphoma
In this global, open-label, randomised trial, epcoritamab plus R² was associated with higher response rates and longer progression-free survival than R² alone, with more frequent grade 3 or higher adverse events reported for the triplet.
The Lancet Group reaches millions of clinicians and researchers worldwide.
Tafasitamab combination linked to longer progression-free survival in investigational follicular lymphoma trial
In a phase 3 randomised trial, adding tafasitamab, which is not currently approved for this combination or indication, to lenalidomide and rituximab was associated with longer progression-free survival versus placebo; overall survival and quality-of-life data are still awaited.
Loncastuximab tesirine plus rituximab explored in relapsed or refractory follicular lymphoma.
In a single-arm, phase 2 study without a comparator arm, investigators reported high response rates in 39 patients, including high-risk subgroups; read the Research in Context.
Epcoritamab in relapsed or refractory follicular lymphoma after two or more prior therapies
In the phase 2 EPCORE NHL-1 trial, optimal treatment duration remains undetermined; investigators reported clinically meaningful activity with manageable safety.
Investigational bispecific antibody shows durable responses in phase 2 follicular lymphoma study, but no head-to-head data yet
In a heavily pretreated population with relapsed or refractory follicular lymphoma who had received two or more previous therapies, investigators reported durable responses with mosunetuzumab; benefit–risk is still being validated in ongoing trials.
Phase 2 study reports responses with tazemetostat in relapsed or refractory follicular lymphoma
In heavily pretreated patients, investigators reported durable responses and a favourable safety profile with tazemetostat, and called for future studies of combination use.
Trial finds 4 Gy not non-inferior to 24 Gy for lymphoma local control
With long-term follow-up, the authors report 4 Gy was not non-inferior to 24 Gy for local control of follicular lymphoma, though 4 Gy may offer pragmatic value for palliative symptom control.
Lenalidomide plus obinutuzumab explored in previously treated follicular lymphoma
The authors describe supporting evidence for this regimen (with lenalidomide maintenance) in relapsed or refractory follicular lymphoma, including subgroups with early disease progression or refractory disease; study design and phase were not stated in the provided text.